Point72 Asset Management’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-388,613
Closed -$9.19M 1374
2019
Q3
$9.19M Sell
388,613
-195,200
-33% -$5.78M 0.06% 372
2019
Q2
$17.6M Buy
583,813
+378,813
+185% +$8.68M 0.09% 275
2019
Q1
$4.59M Buy
205,000
+145,400
+244% +$3.13M 0.02% 571
2018
Q4
$1.08M Sell
59,600
-18,599
-24% -$292K 0.01% 799
2018
Q3
$1.42M Buy
+78,199
New +$927K 0.01% 814
2018
Q1
Sell
-100,000
Closed -$850K 1210
2017
Q4
$850K Buy
+100,000
New +$1.23M ﹤0.01% 815

Other funds holding RARX

Point72 Asset Management's RARX Position: Q4 2019 in Review

Point72 Asset Management sold out of Ra Pharmaceuticals, Inc. Common Stock (RARX) in Q4 2019, closing a stake of 388,613 shares — an estimated $9.19M sold.

Point72 Asset Management first reported a position in RARX in Q4 2017 and held it in 6 quarters. The position peaked at $17.6M in Q2 2019. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

  • Point72 Asset Management reported no remaining Ra Pharmaceuticals, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Point72 Asset Management sold 388,613 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $9.19M.
  • Point72 Asset Management first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 6 quarters.
  • Point72 Asset Management's Ra Pharmaceuticals, Inc. Common Stock position peaked at $17.6M in Q2 2019.
  • 146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Point72 Asset Management's 13F filing for Q4 2019, filed 14 Feb 2020.